Default company panoramic image
Logo

eCloud Genomics

An internet-based company that creates molecular fingerprints; giving cancer patients options, and accelerating the development of new drugs

  • Stage Concept Only
  • Industry Biotechnology
  • Location Tampa, FL, USA
  • Currency USD
  • Website eCloudGenomics.com

Company Summary

eCloud Genomics gives cancer patients options. We are an online personalized medicine platform that connect cancer patients, molecular tests, drugs and clinical trials. Patients or their physicians send us clinical information and/or tumor samples, from which we create a cloud-based, updateable, interactive, genomic fingerprint that serves as a roadmap for the cancer journey; guiding patients to drugs and trials, and clinical trials to patients.

Team

  • Default avatar
    Johnathan M. Lancaster, MD PhD
    Founder and CEO

    A gynecologic oncologist with expertise in molecular genetics and personalised medicine. He has worked at the Moffitt Cancer Center in Tampa, Florida for 9 years, where he currently serves as President of the Moffitt Medical Group and Chair of the Department of Women’s Oncology.

  • Default avatar
    James J. Mule, PhD
    Founder and CSO

    James J. Mulé, PhD has been involved in oncology research and the development of cancer treatments for more than 20 years. Dr. Mulé is an Associate Center Director for Translational Research, and the Director of Cell-Based Therapies at Moffitt Cancer Center. Dr. Mulé is a previous founder of two biotech start-up companies while an adjunct faculty member in the Department of Surgery, Stanford University.

  • Default avatar
    Frank Kiesner, JD
    Business Advisor

    Founder and CEO of OvaGene Oncology Inc., Mr. Kiesner is a successful biotech serial entrepreneur with a footprint in this space, and a previous successful exit from Oncotech. Mr. Kiesner has been a partner at Northstar Ventures, General Council and Treasurer of ADC Telecommunications, as well as being President of ADC Corporation’s Magnetic division.

  • Default avatar
    Robert Sederman, MBH
    Marketing Advisor

    As CEO of Cozint, Mr. Sederman oversaw the development of innovative Web approaches that supported pharmaceutical companies with next-generation research solutions to their sales and marketing concerns. Mr. Sederman has about 20 years of experience in consulting and market research for healthcare companies, and continues to redefine the marketing field for healthcare companies with his ground-breaking insights.

  • Default avatar
    Michael Cerio, MBA, MS
    Business Advisor

    President and CEO of Oncolome Diagnostics. Previously Senior Director of Business Development for Genzyme Corporation with 13 years of industry experience in oncology, personalized medicine, molecular diagnostics and pharmacogenomics. Mr. Cerio has experience with early stage biotechnology companies BG Medicine and Genaissance Pharmaceuticals.

Advisors

  • Default avatar
    Leslie J. Croland, Edwards Wildman Palmer LLP, West Palm Beach, FL; Tel 561.820.0212
    Lawyer
    Unconfirmed
    Default avatar
    Michael I. Daszkal, C.P.A., P.A., Daszkal Bolton LLP, Boca Raton, FL, 561.953.1502
    Accountant
    Unconfirmed